Darbepoetin alfa biosimilar (Nichi-Iko Pharmaceutical/Aprogen)

阿法达贝泊汀生物类似药 (Nichi-Iko Pharmaceutical/Aprogen)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameDarbepoetin alfa biosimilar (Nichi-Iko Pharmaceutical/Aprogen)
Drug Alias Name达贝泊汀α生物仿制药 (Nichi-Iko Pharmaceutical/Aprogen)阿法达贝泊汀生物仿制药 (Nichi-Iko Pharmaceutical/Aprogen)达促红素α生物仿制药 (Nichi-Iko Pharmaceutical/Aprogen)达依泊汀α生物仿制药 (Nichi-Iko Pharmaceutical/Aprogen)阿法达贝汀生物仿制药 (Nichi-Iko Pharmaceutical/Aprogen) +[6
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionErythropoietin receptor agonists
TargetsErythropoietin receptor
Therapy Area/IndicationsAnemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Active IndicationsN/A
Inactive IndicationsAnemia

Other Information

ATC CodeB03XA02
Related LinksN/A